Profile change history

What changed for Degarelix?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Degarelix identity.

63Total events
63Record additions
0Version changes
18Cited source years

Collection chronology

Evidence added to PeptideScanner

Browse all 63 connected records →

Showing the latest 63 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 17, 2026.

Record added

Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques.

PubMed lists PMID 43041099 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2027-01 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 17, 2026
Cited source date
November 17, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT00116753

PeptideScanner retained ClinicalTrials.gov record NCT00116753 at 2026-11-15T21:52:09.579Z. Its registry update date was 2010-12-10, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
December 10, 2010
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00116779

PeptideScanner retained ClinicalTrials.gov record NCT00116779 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-12-19, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
December 19, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00117286

PeptideScanner retained ClinicalTrials.gov record NCT00117286 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
December 18, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00117949

PeptideScanner retained ClinicalTrials.gov record NCT00117949 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-05-23, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
May 23, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00215683

PeptideScanner retained ClinicalTrials.gov record NCT00215683 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-04-01, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
April 1, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00268892

PeptideScanner retained ClinicalTrials.gov record NCT00268892 at 2026-11-15T21:52:09.579Z. Its registry update date was 2010-12-24, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
December 24, 2010
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00295750

PeptideScanner retained ClinicalTrials.gov record NCT00295750 at 2026-11-15T21:52:09.579Z. Its registry update date was 2012-12-19, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
December 19, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00451958

PeptideScanner retained ClinicalTrials.gov record NCT00451958 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-03-21, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
March 21, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00468286

PeptideScanner retained ClinicalTrials.gov record NCT00468286 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-03-23, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
March 23, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00527488

PeptideScanner retained ClinicalTrials.gov record NCT00527488 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-05-04, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
May 4, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00738673

PeptideScanner retained ClinicalTrials.gov record NCT00738673 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-01-18, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
January 18, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00801242

PeptideScanner retained ClinicalTrials.gov record NCT00801242 at 2026-11-15T21:52:09.579Z. Its registry update date was 2014-09-03, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
September 3, 2014
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00818623

PeptideScanner retained ClinicalTrials.gov record NCT00818623 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-30, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
November 30, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00819156

PeptideScanner retained ClinicalTrials.gov record NCT00819156 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-30, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
November 30, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00819247

PeptideScanner retained ClinicalTrials.gov record NCT00819247 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-09, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
November 9, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00947882

PeptideScanner retained ClinicalTrials.gov record NCT00947882 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-06-08, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
June 8, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00967018

PeptideScanner retained ClinicalTrials.gov record NCT00967018 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-01-03, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
January 3, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01071915

PeptideScanner retained ClinicalTrials.gov record NCT01071915 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
February 12, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01215513

PeptideScanner retained ClinicalTrials.gov record NCT01215513 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-05-22, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
May 22, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01220869

PeptideScanner retained ClinicalTrials.gov record NCT01220869 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-04-13, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
April 13, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01696877

PeptideScanner retained ClinicalTrials.gov record NCT01696877 at 2026-11-15T21:52:09.579Z. Its registry update date was 2019-03-28, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
March 28, 2019
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01731912

PeptideScanner retained ClinicalTrials.gov record NCT01731912 at 2026-11-15T21:52:09.579Z. Its registry update date was 2019-01-18, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
January 18, 2019
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01751451

PeptideScanner retained ClinicalTrials.gov record NCT01751451 at 2026-11-15T21:52:09.579Z. Its registry update date was 2021-11-19, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
November 19, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02135445

PeptideScanner retained ClinicalTrials.gov record NCT02135445 at 2026-11-15T21:52:09.579Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
April 13, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02489357

PeptideScanner retained ClinicalTrials.gov record NCT02489357 at 2026-11-15T21:52:09.579Z. Its registry update date was 2021-11-12, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02849990

PeptideScanner retained ClinicalTrials.gov record NCT02849990 at 2026-11-15T21:52:09.579Z. Its registry update date was 2022-01-13, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
January 13, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03069937

PeptideScanner retained ClinicalTrials.gov record NCT03069937 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-10-15, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
October 15, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03689699

PeptideScanner retained ClinicalTrials.gov record NCT03689699 at 2026-11-15T21:52:09.579Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
October 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04397718

PeptideScanner retained ClinicalTrials.gov record NCT04397718 at 2026-11-15T21:52:09.579Z. Its registry update date was 2022-06-06, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
June 6, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05181800

PeptideScanner retained ClinicalTrials.gov record NCT05181800 at 2026-11-15T21:52:09.579Z. Its registry update date was 2024-09-27, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
September 27, 2024
Evidence lane
Clinical trials
Record added

Federal Register notice 2010-4159

The Federal Register published notice 2010-4159, attributed to FDA and its parent HHS department, on 2010-03-01. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRMAGON,” and PeptideScanner's exact reviewed identity mapping connects the document to Degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
March 1, 2010
Evidence lane
Regulatory
Record added

Degarelix for prostate cancer.

PubMed lists PMID 19453267 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2009-06 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
May 26, 2009
Evidence lane
Literature metadata
Record added

Degarelix (firmagon) for prostate cancer.

PubMed lists PMID 19838145 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2009-10-19 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

Degarelix acetate for the treatment of prostate cancer.

PubMed lists PMID 20069136 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-10 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
August 4, 2025
Evidence lane
Literature metadata
Record added

Evaluation of degarelix in the management of prostate cancer.

PubMed lists PMID 21188095 in Cancer management and research as Journal Article, with publication-date metadata of 2010-01-25 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
April 9, 2024
Evidence lane
Literature metadata
Record added

In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.

PubMed lists PMID 21496210 in Basic & clinical pharmacology & toxicology as Journal Article, with publication-date metadata of 2011-05-23 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 20, 2014
Evidence lane
Literature metadata
Record added

Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey.

PubMed lists PMID 21768273 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2011-07-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
February 12, 2025
Evidence lane
Literature metadata
Record added

Degarelix: an antagonist to GnRH--theoretical and treatment considerations in paraphilia.

PubMed lists PMID 22082230 in The journal of sexual medicine as Letter, with publication-date metadata of 2011-11-14 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 19, 2015
Evidence lane
Literature metadata
Record added

Degarelix as a new antiangiogenic agent for metastatic colon cancer?

PubMed lists PMID 23431078 in World journal of gastroenterology as Case Reports, Journal Article, with publication-date metadata of 2013-02-07 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 21, 2021
Evidence lane
Literature metadata
Record added

In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hormone receptor blocker.

PubMed lists PMID 23589543 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2013-04-15 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
February 12, 2025
Evidence lane
Literature metadata
Record added

Management of a patient with locally advanced prostate cancer with degarelix: a case report.

PubMed lists PMID 23783053 in The Canadian journal of urology as Case Reports, Journal Article, with publication-date metadata of 2013-06 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
June 20, 2013
Evidence lane
Literature metadata
Record added

Tipping the balance in favour of degarelix for ADT.

PubMed lists PMID 24473414 in Nature reviews. Urology as Journal Article, with publication-date metadata of 2014-01-28 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 21, 2021
Evidence lane
Literature metadata
Record added

A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.

PubMed lists PMID 24568188 in Journal of medical economics as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-02-25 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
January 28, 2026
Evidence lane
Literature metadata
Record added

Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.

PubMed lists PMID 25851250 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-04-08 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
June 23, 2015
Evidence lane
Literature metadata
Record added

A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.

PubMed lists PMID 27756786 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-10-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 7, 2017
Evidence lane
Literature metadata
Record added

Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.

PubMed lists PMID 28480768 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2017-05-19 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
July 28, 2024
Evidence lane
Literature metadata
Record added

Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.

PubMed lists PMID 28753747 in European urology focus as Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-01-22 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
December 17, 2018
Evidence lane
Literature metadata
Record added

An efficient synthesis of deuterium-labeled degarelix acetate, a third-generation gonadotropin-releasing hormone receptor antagonist.

PubMed lists PMID 28960413 in Journal of labelled compounds & radiopharmaceuticals as Journal Article, with publication-date metadata of 2018-03-15 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
September 11, 2019
Evidence lane
Literature metadata
Record added

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.

PubMed lists PMID 29264358 in Research and reports in urology as Journal Article, with publication-date metadata of 2017-12-06 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 11, 2022
Evidence lane
Literature metadata
Record added

A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermitten…

PubMed lists PMID 29534997 in The Journal of urology as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2018-03-11 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 22, 2021
Evidence lane
Literature metadata
Record added

Prostate Cancer Drug Degarelix Rapidly Treats Pedophilic Disorder.

PubMed lists PMID 32573666 in JAMA as Journal Article, with publication-date metadata of 2020-06-23 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
June 26, 2020
Evidence lane
Literature metadata
Record added

A Real-Time NMR Method for Measurement of In Vitro Aggregation Kinetics Of Degarelix Drug Products.

PubMed lists PMID 33586081 in AAPS PharmSciTech as Journal Article, with publication-date metadata of 2021-02-14 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 24, 2021
Evidence lane
Literature metadata
Record added

Degarelix for treating advanced hormone-sensitive prostate cancer.

PubMed lists PMID 34350976 in The Cochrane database of systematic reviews as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2021-08-05 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
June 23, 2025
Evidence lane
Literature metadata
Record added

[Treatment of advanced hormone-sensitive prostate cancer using degarelix].

PubMed lists PMID 34907463 in Der Urologe. Ausg. A as Journal Article, Review, with publication-date metadata of 2021-12-14 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 10, 2026
Evidence lane
Literature metadata
Record added

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

PubMed lists PMID 34934969 in European urology open science as Journal Article, with publication-date metadata of 2021-11-17 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
July 16, 2022
Evidence lane
Literature metadata
Record added

Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands.

PubMed lists PMID 35069083 in Current urology as Journal Article, with publication-date metadata of 2021-06-25 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
April 30, 2022
Evidence lane
Literature metadata
Record added

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.

PubMed lists PMID 35923949 in Frontiers in public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-07-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 31, 2025
Evidence lane
Literature metadata
Record added

Investigation of the GnRH antagonist degarelix isomerization in biological matrices.

PubMed lists PMID 37455491 in Pharmacology research & perspectives as Journal Article, with publication-date metadata of 2023-08 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
July 19, 2023
Evidence lane
Literature metadata
Record added

Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.

PubMed lists PMID 38413843 in The Prostate as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-27 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
July 24, 2026
Evidence lane
Literature metadata
Record added

Resting state functional connectivity in paedophilic disorder and degarelix treatment.

PubMed lists PMID 41918172 in Acta neuropsychiatrica as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
August 14, 2026
Evidence lane
Literature metadata
Record added

Fatal Interstitial Pneumonitis During Combined Degarelix, Darolutamide, and Docetaxel Therapy for Metastatic Prostate Cancer.

PubMed lists PMID 41970125 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-03-10 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
August 13, 2026
Evidence lane
Literature metadata